These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 26244985)

  • 1. Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.
    Passardi A; Scarpi E; Tamberi S; Cavanna L; Tassinari D; Fontana A; Pini S; Bernardini I; Accettura C; Ulivi P; Frassineti GL; Amadori D
    PLoS One; 2015; 10(8):e0134732. PubMed ID: 26244985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis.
    Silvestris N; Scartozzi M; Graziano G; Santini D; Lorusso V; Maiello E; Barni S; Cinieri S; Loupakis F; Pisconti S; Brunetti AE; Palasciano G; Palmieri VO; Del Prete M; Dell'Aquila E; Latiano TP; Petrelli F; Lutrino S; Rossini D; Giampieri R; Lotesoriere C; Cascinu S
    Expert Opin Biol Ther; 2015 Feb; 15(2):155-62. PubMed ID: 25411089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial.
    Giampieri R; Puzzoni M; Daniele B; Ferrari D; Lonardi S; Zaniboni A; Cavanna L; Rosati G; Pella N; Zampino MG; Sozzi P; Germano D; Zagonel V; Codecà C; Libertini M; Labianca R; Cascinu S; ; Scartozzi M
    Br J Cancer; 2017 Oct; 117(8):1099-1104. PubMed ID: 28926529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients.
    Scartozzi M; Giampieri R; Maccaroni E; Del Prete M; Faloppi L; Bianconi M; Galizia E; Loretelli C; Belvederesi L; Bittoni A; Cascinu S
    Br J Cancer; 2012 Feb; 106(5):799-804. PubMed ID: 22315053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.
    Marmorino F; Salvatore L; Barbara C; Allegrini G; Antonuzzo L; Masi G; Loupakis F; Borelli B; Chiara S; Banzi MC; Miraglio E; Amoroso D; Dargenio F; Bonetti A; Martignetti A; Paris M; Tomcikova D; Boni L; Falcone A; Cremolini C
    Br J Cancer; 2017 Jan; 116(3):318-323. PubMed ID: 28081548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial.
    Ulivi P; Scarpi E; Passardi A; Marisi G; Calistri D; Zoli W; Del Re M; Frassineti GL; Tassinari D; Tamberi S; Vertogen B; Amadori D
    J Transl Med; 2015 Aug; 13():258. PubMed ID: 26259598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer.
    Passardi A; Scarpi E; Cavanna L; Dall'Agata M; Tassinari D; Leo S; Bernardini I; Gelsomino F; Tamberi S; Brandes AA; Tenti E; Vespignani R; Frassineti GL; Amadori D; De Giorgi U
    Oncotarget; 2016 May; 7(22):33210-9. PubMed ID: 27120807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy.
    Ulivi P; Scarpi E; Chiadini E; Marisi G; Valgiusti M; Capelli L; Casadei Gardini A; Monti M; Ruscelli S; Frassineti GL; Calistri D; Amadori D; Passardi A
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28598398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab.
    Uysal M; Bozcuk H; Sezgin Göksu S; Murat Tatli A; Arslan D; Gündüz S; Senol Coskun H; Ozdogan M; Savas B
    Biomed Pharmacother; 2014 May; 68(4):409-12. PubMed ID: 24721326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.
    Bar J; Spencer S; Morgan S; Brooks L; Cunningham D; Robertson J; Jürgensmeier JM; Goss GD
    Clin Colorectal Cancer; 2014 Mar; 13(1):46-53. PubMed ID: 24355210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
    Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
    Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
    Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
    Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
    Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
    Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lactate Dehydrogenase Is a Useful Marker for Predicting the Efficacy of Bevacizumab-containing Chemotherapy in Patients With Metastatic Colorectal Cancer.
    Shibutani M; Maeda K; Kashiwagi S; Nagahara H; Fukuoka T; Iseki Y; Wang EN; Okazaki Y; Hirakawa K; Ohira M
    Anticancer Res; 2021 Jul; 41(7):3535-3542. PubMed ID: 34230149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
    Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study.
    Casadei-Gardini A; Scarpi E; Ulivi P; Palladino MA; Accettura C; Bernardini I; Spallanzani A; Gelsomino F; Corbelli J; Marisi G; Ruscelli S; Valgiusti M; Frassineti GL; Passardi A
    Cancer Manag Res; 2019; 11():4357-4369. PubMed ID: 31191000
    [No Abstract]   [Full Text] [Related]  

  • 19. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
    Antonuzzo L; Giommoni E; Pastorelli D; Latiano T; Pavese I; Azzarello D; Aieta M; Pastina I; Di Fabio F; Bertolini A; Corsi DC; Mogavero S; Angelini V; Pazzagli M; Di Costanzo F
    World J Gastroenterol; 2015 Jun; 21(23):7281-8. PubMed ID: 26109816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
    Bennouna J; Sastre J; Arnold D; Österlund P; Greil R; Van Cutsem E; von Moos R; Viéitez JM; Bouché O; Borg C; Steffens CC; Alonso-Orduña V; Schlichting C; Reyes-Rivera I; Bendahmane B; André T; Kubicka S;
    Lancet Oncol; 2013 Jan; 14(1):29-37. PubMed ID: 23168366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.